TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01335399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets, Oral, 28 mg, once daily, on Days 1, 8, 15, 22 (cycles 1\&2) ; Days 1 \&15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets, Oral, 40 mg, once daily, on Days 8 \& 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Solution, Intravenous (IV), 8 mg, Once daily, on Days 1, 8, 15, 22 (cycles 1\&2) ; Days 1 \&15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
Study: NCT04410107

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise physiology
Description: Cardiopulmonary exercise test (CPET)

Intervention type: DIAGNOSTIC_TEST
Intervention: Health-related quality of life
Description: Short-Form Health Survey Questionnaire (SF-36)

Intervention type: DIAGNOSTIC_TEST
Intervention: Health-related quality of life
Description: Short-Form Health Survey Questionnaire (SF-36)

Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening
Description: 1. Adapted translation American Thoracic Society respiratory symptoms questionnaire;~2. Beck Anxiety Inventory (BAI) and Beck's depression Inventory (BDI);~3. Questionnaire for screening for post-traumatic stress symptoms (PTSD).

Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening
Description: 1. Adapted translation American Thoracic Society respiratory symptoms questionnaire;~2. Beck Anxiety Inventory (BAI) and Beck's depression Inventory (BDI);~3. Questionnaire for screening for post-traumatic stress symptoms (PTSD).
Study: NCT05796219

Intervention type: RADIATION
Group type: OTHER
Intervention: Low dose mammogram
Description: Low dose mammogram
Study: NCT03239535

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intramuscular injection
Study: NCT00722358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-650032
Description: Capsule, Oral, Q12h, 3/5 days~Panel 1: 200 mg~Panel 2: 400 mg~Panel 3: 600 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, Q 12h, 3/5 days~Panel 1: matching placebo~Panel 2: matching placebo~Panel 3: matching placebo
Study: NCT05798182

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound measurement
Description: Study was conducted with Mindray T7 ultrasound machine using linear probe. Vascular ultrasound mode was used with settings depth of 50 mm and gain of 40 dB during the entire study period. The diameter and flow velocity of the brachial artery and wrist edema of the fist were measured within 24 hours of admission and the following day.
Study: NCT01335399

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab (BMS-901608; HuLuc63)
Description: Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1\&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab (BMS-901608; HuLuc63)
Description: Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
Study: NCT00524576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: One dose (10µg Hepatitis B surface antigen (HBsAg))

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: One dose (10µg Hepatitis B surface antigen (HBsAg))
Study: NCT00409188

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tecemotide (L-BLP25)
Description: After receiving cyclophosphamide, participants will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance vaccinations with 806 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until disease progression is documented.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single low dose cyclophosphamide
Description: A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before first tecemotide (L-BLP25) vaccination.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single infusion (IV) of 0.9% Saline solution instead of cyclophosphamide but in the same calculated dose will be given three days before first placebo vaccination. Subjects will then receive eight consecutive weekly subcutaneous vaccinations with placebo at weeks 0; 1; 2; 3; 4; 5; 6 and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at week 13, until disease progression is documented.
Study: NCT02593188

Intervention type: BIOLOGICAL
Intervention: HYQVIA
Description: Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase

Intervention type: BIOLOGICAL
Intervention: HYQVIA
Description: Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
Study: NCT02328261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib (125 mg tablet) is orally administered three times daily until disease progression or unaccepted toxicity.
Study: NCT02165566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular-insulin
Description: patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro-insulin
Description: patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion
Study: NCT03456362

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION
Description: theta burst stimulation (TBS) is a novel form of repetitive transcranial magnetic stimulation that mimics protocols inducing long-term potentiation (LTP) or long-term depression (LTD) in animal models. Whereas continuous TBS (cTBS) induces long-lasting inhibition of cortical areas, iTBS exerts the opposite effect, increasing cerebellar excitability

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION
Description: theta burst stimulation (TBS) is a novel form of repetitive transcranial magnetic stimulation that mimics protocols inducing long-term potentiation (LTP) or long-term depression (LTD) in animal models. Whereas continuous TBS (cTBS) induces long-lasting inhibition of cortical areas, iTBS exerts the opposite effect, increasing cerebellar excitability
Study: NCT02964897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-support plus usual care from the Health Care for Reentry Veterans program
Description: a peer mentor who is also a veteran will establish a relationship with each subject and provide instrumental and emotional support to the subject during the first 6 months of the subject's release from incarceration. This is in addition to the usual reentry support provided by the Health Care for Reentry Veterans program.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care from the Health Care for Reentry Veterans program
Description: Health Care for Reentry Veterans program provides reentry planning while the veteran is incarcerated. An outreach worker visits the veteran in the incarceration facility to conduct a needs assessment and help create a reentry plan to cover issues such as where they will be housed, what health care appointments they will need in the first 30 days, whether they need legal assistance, etc.
Study: NCT01260480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [18F]-ML-10 in conjunction with PET imaging
Description: Subjects will receive two to three intravenous (IV) doses of \[18F\]-ML-10. The dose for each \[18F\]-ML-10 dose will be 5.50 MBq/Kg or 0.15 mCi/Kg but will not exceed 500.00 MBq (13.50 mCi) per administration.
Study: NCT03604354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol 100 MG Oral Tablet
Description: This arm will receive drugs one hour before undergoing unilateral total knee arthroplasty. Interventions tapentadol 100mg oral tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: This arm will receive drugs one hour before undergoing unilateral total knee arthroplasty. Interventions pregabalin 150mg oral tablets.
Study: NCT01411670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human protein C concentrate
Description: Continuous infusion of human protein C concentrate at the dose of 3 UI/Kg/Hr to reach a protein C plasma activity of 70-120%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Activated protein C
Description: Continuous infusion of activated protein C at the dose of 24 micrograms/Kg/Hr for 96 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Standard treatment
Study: NCT03301428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retrain pain educational website
Description: Patients in this group will be invited to consult an educational website developped for patients with chronic pain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Booklet
Description: Patients in this group will be invited toread an educational booklet developped for patients with chronic pain
Study: NCT03179839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Therapy
Description: The intervention will be carried out according to the handbook of the Dr. Didonna. There is a Session Agenda from Dr. Didonna for the use of the Instructor and session handouts for the participants. Some records of mindfulness practices will be given to participants for facilitating practice between sessions. Before each session, the instructor needs to review the session agenda and prepare copies of handouts for participants.~MBCT instructors were experienced psychotherapists and psychiatrists with several years' expertise in OCD treatment. They had been trained by one of the founders of MBCT, Mark Williams and the founder of MBCT for OCD, Fabrizio Didonna. Supervision will be provided by Dr.Didonna.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psycho-education Program
Description: As a widely used placebo control condition, the Psycho-Education Program can play an active role through the psychological suggestion and forward thinking mostly. It is designed to be similar with MBCT in level of structure, setting and other non-specific effects of psychological intervention. All instructors will be qualified graduate students who major in clinical psychology with training in cognitive behavioral therapy and psychodynamic therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline, fluvoxamine
Description: The participants can be adjustable once a week dose and the maximum dose does not exceed the maximum amount of instructions. And benzodiazepine drugs also can be used by the OCD patients with sleep disorders, but not be used continuously for more than two weeks. Besides this, other psychotropic drugs are not allowed to use. The use of drugs in this study are commonly used drugs with good safety, and its common adverse reactions include dry mouth, constipation, nausea, indigestion, dizziness, fatigue, sweating and so on.
Study: NCT04686903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epiduroscopy treatment
Description: Device Epiduroscop, procedure mecahnical lysis, laser, radiofrequency + drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline) Follow-up: before procedure, 6 months and 12 months after procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Racz catheter epidural procedure
Description: Device Racz catheter, two procedures during clinical trial observation~* First procedure after enrolment into the study mechanical lysis and drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)~* Second procedure after 6 months mechanical lysis + drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caudal epidural block
Description: Technique Caudal epidural block~Three procedures during clinical trial observation :~* First procedure after enrolment into the study drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg and solution of hyaluronidase 150 I.U. in 10mL of saline)~* Second procedure after 4 months drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg)~* Third procedure after 8 months drug administration into the epidural space (corticosteroid methylprednisolone acetate 80mg)
Study: NCT00833989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK249320
Description: I.V. infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo
Study: NCT00588133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: Loading dose: 6.6 mg/kg Prime dose: 50 mg for 2.5 Liter circuit (assuming 1 L/kg Vd in prime fluids), 40 mg for 2 Liter circuit Rate of infusion: 6 mg/kg/hr~Renal Insufficiency (normal loading dose and prime dose):~Serum Creatinine = 1.6-3.3: reduce infusion to 4.5 mg/kg/hr Serum Creatinine = 3.3-6.6: reduce infusion to 3.0 mg/kg/hr Serum Creatinine = \>6.6: reduce infusion to 1.5 mg/kg/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid
Description: 10 mg/kg tranexamic acid given over 20 minutes followed by an infusion of 1 mg/kg/hr
Study: NCT03966300

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-faceted knowledge translation intervention
Description: The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
Study: NCT03003715

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scans
Description: Two 90 minute scans whose maximum radiological dose is 15 mCi \[11 C\] carfentanil, a selective and specific mu-opioid receptor radioligand. The first one provided baseline data, and the second occurred with the sequence of sham tDCS and tDCS as described in each arm description.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scans
Description: Two 90 minute scans whose maximum radiological dose is 15 mCi \[11 C\] carfentanil, a selective and specific mu-opioid receptor radioligand. The first one provided baseline data, and the second occurred with the sequence of sham tDCS and tDCS as described in each arm description.
Study: NCT03379727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Induction Phase: 50 mg (two 25 mg capsules) twice a day by mouth on days 8-28, for 1 - 2 cycles; a cycle = 28 days; Consolidation Phase: 50 mg (two 25 mg capsules) twice a day by mouth on days 8-28, for up to 4 cycles; Maintenance Phase: Continuous dosing (days 1 - 28) for up yo 12 cycles or until relapse, unacceptable toxicity, death, physician's decision, subject/guardian decision, protocol deviation, study termination by Sponsor, lost to follow-up, technical problems, pregnancy, subject withdrew consent, or until the end of study, whichever event occurred first.
Study: NCT03003715

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: In active tDCS, a 2 milli-amp transcranial direct current stimulation is for 20 minutes.
Study: NCT03379727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction Phase (standard dose) (7 + 3 arm): 100-200 mg/m2/day by Continuous intravenous infusion (CIVI) days 1-7 (168 hours infusion); Induction Phase (5 + 2 arm): 100 mg/m2/day by CIVI days 1-5; Consolidation Phase: 1-3 g/m2 infusion over 3 hours every 12 h on days 1, 3 and 5, up to 4 cycles based on age and per investigator discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anthracycline ((daunorubicin or idarubicin): Induction Phase only
Description: daunorubicin (7 + 3 arm): 60-90 mg/m2/day by IV push on days 1-3 (with standard-dose cytarabine); daunorubicin (5 + 2 arm): 60 mg/m2/day by IV push on days 1-2; idarubicin (7 + 3 arm): 12 mg/m2/day by IV push on days 1-3 (with standard-dose cytarabine); idarubicin (5 + 2 arm): 12 mg/m2/day by IV push on days 1-2
Study: NCT02899182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide NO
Description: The NO group receive local anesthesia at the puncture site plus inhalation N2O-O2 mixture by self-demand valve

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: O2
Description: the conventional group (C) will receive local anesthesia at the puncture site plus inhalation of 100% oxygen a face mask.
Study: NCT01806051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuvan
Description: Only PKU participants (Arm 1) will be administered Kuvan once daily either at a dose of 20 mg/kg/day (if the PKU participant is not currently taking Kuvan) or at the subject's regular dose (if the PKU participant is currently taking Kuvan). They will remain on Kuvan for 4 weeks.
Study: NCT01783990

Intervention type: DRUG
Intervention: Hydroxyurea
Description: Parents and child's doctor may plan to use or not to use hydroxyurea.

Intervention type: DRUG
Intervention: Hydroxyurea
Description: Parents and child's doctor may plan to use or not to use hydroxyurea.
Study: NCT00251238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761
Description: daily Ginkgo biloba extract EGb 761

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ginkgo biloba extract EGb 761
Description: daily Ginkgo biloba extract EGb 761
Study: NCT02000245

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: verbal expression for compassion
Description: The doctor going to perform bronchoscopy tells a short sentence to a patient. (Hello, I'm Dr.OO. During this test, I will keep an eye on you. Don't worry)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: verbal expression for compassion
Description: The doctor going to perform bronchoscopy tells a short sentence to a patient. (Hello, I'm Dr.OO. During this test, I will keep an eye on you. Don't worry)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: touch
Description: The doctor going to perform bronchoscopy puts a hand on the patient's shoulder
Study: NCT03461068

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone monoester
Description: Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior a 2-hour oral glucose tolerance test.
Study: NCT03461068

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acute ingestion of a taste-matched placebo prior a 2-hour oral glucose tolerance test.
Study: NCT00941187

Intervention type: OTHER
Intervention: diffusion NO/CO method
Description: pulmonary capillary blood volume (Vc), measured by the double diffusion NO/CO method: this method is to inhale during a deep inspiration with a mixture of helium (8-10%), CO (2000 ppm) and NO (20-40 ppm), the O2 (21%)
Study: NCT03003715

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: No radiotracer is used; 3 tesla scanner; all participants have MRI prior to PET scans.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: No radiotracer is used; 3 tesla scanner; all participants have MRI prior to PET scans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sham tDCS (prior to real tDCS)
Description: For sham tDCS, current is applied only for 30 seconds, as sensations arising from tDCS treatment occur only at the beginning of application; however the equipment will be on the participant for 20 minutes to match that of the active tDCS application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sham tDCS (prior to real tDCS)
Description: For sham tDCS, current is applied only for 30 seconds, as sensations arising from tDCS treatment occur only at the beginning of application; however the equipment will be on the participant for 20 minutes to match that of the active tDCS application.
Study: NCT04642495

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual acuity testing with SW , Landolt-C and Tumbling-E symbols
Description: Establish prediction intervals for acuity tests
Study: NCT03939871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluvestrant + oral vinorelbine
Description: Eligible patients will be treated with the fluvestrant + oral vinorelbine regimen until the disease progresses or intolerable toxicity
Study: NCT02023099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABT-450/r/ABT-267
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study: NCT05055141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care to Share poster
Description: The Care to Share poster enabled patients to share written information about who they are as people with their hospital caregivers.
Study: NCT00847223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZARNESTRA (Tipifarnib)
Study: NCT01358175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (75 mg)
Description: Secukinumab (75 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (150 mg)
Description: Secukinumab (150 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo